Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADU-623
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
ADU-623 is a bivalent, live-attenuated Listeria monocytogenes-based therapeutic cancer vaccine engineered to express two tumor-associated antigens: EGFRvIII (epidermal growth factor receptor variant III) and NY-ESO-1 (cancer/testis antigen 1). The vaccine is designed to stimulate robust tumor-specific immune responses against cells expressing these antigens, which are commonly found in glioblastoma and other high-grade astrocytomas. In addition to eliciting adaptive immunity targeting EGFRvIII and NY-ESO-1, the live Listeria vector also induces potent innate immune activation that may contribute to anti-tumor effects even in the absence of these neoantigens. The primary clinical development has focused on patients with recurrent or treated WHO Grade III/IV astrocytic tumors following standard therapy[1][5][6][7][10].
- Other names
- Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on ADU-623.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADU-623.